Answers are grounded in this paper and cite their sources.
Importance Progression-free survival (PFS) is a widely accepted primary end point in metastatic breast cancer (mBC) trials; however, it remains susceptible to assessment bias. To reduce this risk, blinded independent central review (BICR) is often incorporated into trial designs, but emerging evidence has suggested discordance between investigator- and BICR-assessed PFS. Objective To compare BICR- and investigator-assessed PFS of patients with hormone receptor–positive/ ERBB2 -negative mBC. Data Sources PubMed, Embase, CENTRAL, and major conference proceedings were searched from database inception to November 27, 2025, to identify all potential eligible studies. Study Selection Phase 2 or 3 randomized clinical trials (RCTs) including patients with hormone receptor–positive/ ERBB2 -negative mBC with progression following CDK4/6 inhibitor therapy. Eligible studies required or permitted prior CDK4/6 inhibitor use and reported PFS assessed by both local investigators and BICR. Data Extraction and Synthesis Data from the eligible RCTs were extracted by 2 reviewers (L.V.R. and Z.B.). A trial-level random-effect meta-analysis was performed. Main Outcomes and Measures Outcomes were the discrepancy index (DI)—the ratio of hazard ratios for BICR- vs investigator-assessed PFS—and the absolute difference in median PFS between the 2 assessments. Results Of 4989 identified records, 21 RCTs with 9165 patients met inclusion criteria. Eleven RCTs used BICR as the primary assessment, 13 were open label, and 7 required prior treatment with CDK4/6 inhibitors as an inclusion criterion. No statistically significant difference was observed between investigator- and BICR-assessed PFS overall, with a DI of 1.02 (95% CI, 0.95-1.10; P = .57), which was consistent across meta-regression analyses. The pooled PFS difference was 0.26 months (95% CI, −0.16 to 0.68 months; P = .22) in interventional arms and 0.44 months (95% CI, 0.09-0.78 months; P = .01) in control arms. Conclusions and Relevance Results of this systematic review and meta-analysis show that despite a trend toward longer median PFS with BICR in recent RCTs of patients with hormone receptor–positive/ ERBB2 -negative mBC, there was no statistically significant DI between BICR- and investigator-assessed PFS. Results were consistent across meta-regression analyses and in outlier trials, suggesting that both approaches yield comparable PFS estimates.
No takes yet. Share an insight, caveat, or question.
Ravani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: